

November 26, 2018



Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum

DURHAM, NC / ACCESSWIRE / November 26, 2018/ [Heat Biologics, Inc.](#) (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has been invited to participate in a panel presentation, entitled *Gene & Cell Therapy: The Next Wave of Precision Medicine Panel*, at 12:30 pm HKT on Tuesday, November 27th at the Goldman Sachs Asia Pacific Healthcare Forum in Hong Kong. John Prendergast, Ph.D., Heat's Lead Director, will be presenting.

The event will feature leading public and private healthcare companies with ongoing or planned activities in China. The forum is by invitation only.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immunomodulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our *ComPACT* technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com.

SOURCE: Heat Biologics, Inc.